PE20000270A1 - Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol - Google Patents

Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Info

Publication number
PE20000270A1
PE20000270A1 PE1999000123A PE00012399A PE20000270A1 PE 20000270 A1 PE20000270 A1 PE 20000270A1 PE 1999000123 A PE1999000123 A PE 1999000123A PE 00012399 A PE00012399 A PE 00012399A PE 20000270 A1 PE20000270 A1 PE 20000270A1
Authority
PE
Peru
Prior art keywords
alkyl
purin
diol
derivatives
ethylamine
Prior art date
Application number
PE1999000123A
Other languages
English (en)
Inventor
Brian Cox
Richard Peter Charles Cousins
Chuen Chan
Caroline Mary Cook
Hazel Joan Dyke
David Bays
Stephen Swanson
Joanna Victoria Geden
Frank Ellis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20000270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20000270A1 publication Critical patent/PE20000270A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A DERIVADOS DE 2-(PURIN-9-IL)-TETRAHIDROFURAN-3,4-DIOL DE FORMULA I, R1 Y R2 SON CICLOALQUIL C3-C8, H, R4R5N-ALQUILO C1-C6, GRUPO a, GRUPO b, -(CH2)fSO2NHg(ALQUILO C1-C4)2-g, CICLOALQUILO C3-C8 OPCIONALMENTE SUSTITUIDO POR -(CH2)pR6, ENTRE OTROS; R3 ES METILO, ETILO, -CH=CH2, n-PROPILO, -CH2CH=CH2, (CH2)qHALOGENO, -(CH2)hY(CH2)iH, -COO(CH2)lH, -CON(CH2)mH((CH2)nH), -CO(CH2)oH, -C((CH2)uH)=NO(CH2)vH, ENTRE OTROS; Y ES O, S, N(CH2)jH; a Y b SON 0-4; 3¾a+b¾5; c, d, e SON 0-3; 2¾c+d+e¾3; f ES 2 o 3; g ES 0-2; p ES 0 o 1; q ES 1 o 2; h ES 1 o 2; i ES O A 1; 1¾h+i¾2; j ES 0-1; 1¾h+i+j¾2; l ES 1-2; m Y n SON 0-2; 0¾m+n¾2; o ES 0-2; u Y v SON 0 o 1; 0¾u+v¾1; R4 Y R5 SON H, ALQUILO C1-C6, ARILO, ARILALQUILO C1-C6, NR4R5, ENTRE OTROS; R6 ES OH, NH2, NHCOCH3, HALOGENO; R7 ES H, ALQUILO C1-C6, ALQUIL C1-C6(ARILO), -CO(ALQUILO C1-C6); X ES NR7, O, S, SO, SO2. UN COMPUESTO PREFERIDO ES (2R,3R,4S,5S)-2-(6-(2,2-DIFENIL-ETILAMINO)-2-[2-(1-METIL-1H-IMIDAZOL-4-IL)-ETILAMINO]-PURIN-9-IL)-5-(3-ETIL-[1,2,4]OXADIAZOL-5-IL)-TETRAHIDRO-FURAN-3,4-DIOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION, Y A COMPUESTOS INTERMEDIOS. EL COMPUESTO I ES AGONISTA DEL RECEPTOR A2a DE ADENOSINA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ASMA
PE1999000123A 1998-02-14 1999-02-11 Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol PE20000270A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
PE20000270A1 true PE20000270A1 (es) 2000-05-20

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000123A PE20000270A1 (es) 1998-02-14 1999-02-11 Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Country Status (32)

Country Link
US (1) US6610665B1 (es)
EP (1) EP1056759B1 (es)
JP (1) JP2002503669A (es)
KR (1) KR20010082512A (es)
AP (1) AP2000001881A0 (es)
AR (1) AR017457A1 (es)
AT (1) ATE223429T1 (es)
AU (1) AU757156B2 (es)
BR (1) BR9907886A (es)
CA (1) CA2319009A1 (es)
CO (1) CO4990969A1 (es)
DE (1) DE69902758T2 (es)
DK (1) DK1056759T3 (es)
EA (1) EA200000759A1 (es)
EE (1) EE200000358A (es)
ES (1) ES2183516T3 (es)
HK (1) HK1032062A1 (es)
HR (1) HRP20000538A2 (es)
HU (1) HUP0100702A3 (es)
IL (1) IL137402A0 (es)
IS (1) IS5576A (es)
MA (1) MA27121A1 (es)
NO (1) NO20004045L (es)
NZ (1) NZ505812A (es)
PE (1) PE20000270A1 (es)
PL (1) PL342396A1 (es)
PT (1) PT1056759E (es)
SK (1) SK12002000A3 (es)
SV (1) SV1999000016A (es)
TR (1) TR200002355T2 (es)
WO (1) WO1999041267A1 (es)
YU (1) YU50800A (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
CA2711637A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
KR20140077916A (ko) 2011-09-15 2014-06-24 노파르티스 아게 티로신 키나제로서의 6-치환된 3-(퀴놀린-6-일티오)-[1,2,4]트리아졸로[4,3-a]피라딘
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
AU750462B2 (en) * 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Also Published As

Publication number Publication date
CO4990969A1 (es) 2000-12-26
JP2002503669A (ja) 2002-02-05
EP1056759B1 (en) 2002-09-04
TR200002355T2 (tr) 2000-11-21
ES2183516T3 (es) 2003-03-16
EA200000759A1 (ru) 2001-04-23
DE69902758T2 (de) 2003-05-15
PL342396A1 (en) 2001-06-04
DE69902758D1 (de) 2002-10-10
HUP0100702A3 (en) 2003-01-28
IL137402A0 (en) 2001-07-24
SV1999000016A (es) 1999-10-27
AU757156B2 (en) 2003-02-06
EE200000358A (et) 2001-10-15
AR017457A1 (es) 2001-09-05
DK1056759T3 (da) 2003-01-06
HUP0100702A2 (hu) 2002-01-28
US6610665B1 (en) 2003-08-26
PT1056759E (pt) 2003-01-31
ATE223429T1 (de) 2002-09-15
HRP20000538A2 (en) 2000-12-31
AP2000001881A0 (en) 2000-09-30
EP1056759A1 (en) 2000-12-06
AU2623599A (en) 1999-08-30
MA27121A1 (fr) 2005-01-03
HK1032062A1 (en) 2001-07-06
BR9907886A (pt) 2000-10-17
YU50800A (sh) 2003-04-30
SK12002000A3 (sk) 2001-07-10
NZ505812A (en) 2002-03-01
NO20004045D0 (no) 2000-08-11
KR20010082512A (ko) 2001-08-30
CA2319009A1 (en) 1999-08-19
NO20004045L (no) 2000-08-11
IS5576A (is) 2000-07-25
WO1999041267A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
PE20000270A1 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
PE20000280A1 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
DK1392312T3 (da) Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister
PE20010430A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20020213A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
CN1152042C (zh) 部分或完全a1激动剂-n6杂环5’硫代腺苷衍生物
RU92016415A (ru) Нейрозащитные производные индолона и родственные производные
CN102504001B (zh) 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
PE20010755A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20030256A1 (es) Nucleosidos 4 sustituidos como inhibidores de la replicacion del arn del virus de la hepatitis c
PE20130242A1 (es) Derivados de isoxazolo-piridina
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
ATE405270T1 (de) Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten
NZ522326A (en) Adenosine A2A receptor antagonists
ATE147074T1 (de) Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
PE20000013A1 (es) Derivados de adenosina
KR950032263A (ko) 2'-에테르 그룹을 갖는 뉴클레오사이드 및 올리고 뉴클레오타이드
ATE261982T1 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
ATE471323T1 (de) Purinderivate als antagonisten an purinergen rezeptoren
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
ATE407935T1 (de) Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren
PE20061371A1 (es) Derivados de 2-metil-4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina
CN101212968B (zh) 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
DE69935849D1 (de) Optisch aktive aminopentan-derivate
KR930019640A (ko) 테트라히드로피리미딘 유도체

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed